Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 May 2019 Photo Charl Devenish
UFS Africa celebration
I am not African because I was born in Africa, but because Africa was born in me,” Kwame Nkrumah, Ghana’s first president, and a founding father of the African Union.

Since the African Union’s establishment in 1963, the continent marks Africa Day on 25 May annually. To commemorate the achievements made by African leaders 56 years ago to decolonise the continent and pave the way for a united front on the global stage, the University of the Free State (UFS) hosts various events.

Ubuntu our beginning, ubuntu our ending 

The university celebrated Africa Day a day early this year. The Office for International Affairs coordinated the 2019 Africa Day Reflection and Celebration on 24 May 2019 at the Bloemfontein Campus. A dialogue session delved into the question of what ubuntu has evolved to mean in modern-day society and how best it can be embodied.

Moderator of the dialogue, Ace Moloi, reckoned that “we have a right not only to give ubuntu but to demand and invoke it from other people.” Staff, students and panellists engaged on the aphorism umuntu ngumuntu ngabantu and whether the philosophical principle is a pragmatic way of doing things or is only referred to when self-correcting.

Prof Colin Chasi, from the UFS Department of Communication Science, touched on how ubuntu is embedded in many Nguni languages. A case in point being the implied presence and connectivity typical found in indigenous language greetings. Other panellists including Prof Karin van Marle( Public Law lecturer at the UFS), Thapelo Mokoatsi,History lecturer at the UFS and Matau Setshase, UFS researcher, made contributions on decolonisation, individual identity, reconciliation, social issues, and traditional healers. The consensus reached was that a lot work still needs to be done in understanding and living the values represented by ubuntu.

Qwaqwa Campus Celebration

The Office for International Affairs (OIA) also hosted the first Annual Africa Day Student Dialogue on the Qwaqwa Campus under the theme: Health, Wellbeing, Access, Social inclusion, Equity and Equality on the African continent.

Africa Day Memorial Lecture

Presenting the 2019 Africa Day Memorial Lecture, Prof Francis Nyamnjoh, from University of Cape Town, delved into the topic of Ubuntuism and Africa: Actualised, Misappropriated, Endangered and Reappraised. “I seek to give currency to concepts such African communitarianism, ubuntu, Africanness, Afrocentricity, Afrocentrism, Africanity, Afrikology, humanness, wholeness and reciprocal altruism,” he said.

Hosted by the Centre for Gender and Africa Studies on 22 May 2019 the annual lecture is a calendar constant which reflects on the importance of celebrating the continent and its people.
 
Migration debate unpacked borders 

The UFS Debate Society reflected on borders and migration in Southern Africa on 21 May 2019. The debate unpacked the topic: The Southern African Development Community should develop a free internal migration policy. 

Lecturers also delivered presentations that dissected African societies, the nine frontier wars between the British and amaXhosa that formed South Africa’s borders, and the influence of labour and capital on migration. In closing, African international students shared their lived experiences, hardships and triumphs within the continent.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept